Last reviewed · How we verify
Trasylol (APROTININ)
Trasylol (Aprotinin) is a small molecule antifibrinolytic agent developed by Bayer Healthcare, targeting plasminogen to prevent excessive bleeding. It was FDA-approved in 1993 for the treatment of hemorrhage. As a patented product, its commercial status is proprietary to Bayer Healthcare. Key safety considerations include potential allergic reactions and interactions with other medications. Trasylol works by inhibiting the activity of plasminogen, a protein involved in the breakdown of blood clots.
At a glance
| Generic name | APROTININ |
|---|---|
| Sponsor | Bayer |
| Drug class | Antifibrinolytic Agent |
| Target | Plasminogen |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1993 |
Approved indications
- Hemorrhage
Common side effects
Key clinical trials
- Expression of Protein Tyrosine Phosphatase 1B (PTP1B) and Body Composition Modification in Patients With Septic Shock (NA)
- New Microbiota-endocrine Axis in Fructose Malabsorption-caused Visceral Hypersensitivity in Irritable Bowel Syndrome. (NA)
- Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment (PHASE3)
- Fibrin Glue After ESD for High Risk Patients of Bleeding (NA)
- A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC (PHASE2)
- Sensory Recovery of Digital Nerves After Microsurgical Epineural Neurorrhaphy Alone or in Combination With Tisseel - RET (NA)
- The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy (PHASE4)
- AProtinin Versus Tranexamic Acid in Cardiac Surgery Patients With High-risk for Excessive Bleeding
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trasylol CI brief — competitive landscape report
- Trasylol updates RSS · CI watch RSS
- Bayer portfolio CI